WGC
AVXL icon

Watts Gwilliam & Co’s Anavex Life Sciences AVXL Stock Holding History

Watts Gwilliam & Co’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$126K Hold
109,000
– – 0.02% 217
2025
Q2 		$93.6K Hold
109,000
– – 0.02% 216
2025
Q1 		$153K Buy
+109,000
New +$1.03M 0.03% 204

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $1.74B AUM 32.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Watts Gwilliam & Co's AVXL Position: Q3 2025 in Review

Watts Gwilliam & Co held its Anavex Life Sciences (AVXL) position steady in Q3 2025 at 26,000 shares worth $231K. The position accounts for 0.04% of the portfolio, ranked #200.

Watts Gwilliam & Co first reported a position in AVXL in Q4 2024 and has held it in 4 quarters since. The position peaked at $350K in Q4 2024. 186 funds tracked by Wall St. Rank hold AVXL as of Q3 2025.

  • Watts Gwilliam & Co held 26,000 shares of Anavex Life Sciences worth $231K as of Q3 2025.
  • Watts Gwilliam & Co left its Anavex Life Sciences share count unchanged in Q3 2025.
  • Anavex Life Sciences made up 0.04% of Watts Gwilliam & Co's portfolio in Q3 2025, its #200 holding.
  • Watts Gwilliam & Co first reported a position in Anavex Life Sciences in Q4 2024 and has held it in 4 quarters since.
  • Watts Gwilliam & Co's Anavex Life Sciences position peaked at $350K in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2025.

Based on Watts Gwilliam & Co's 13F filing for Q3 2025, filed 21 Nov 2025.